Fig. 3

Hemin-MSC-EXO treatment ameliorated cardiomyocyte senescence and inhibited mitochondrial fission in infarcted hearts of mice. A Representative images of SA-β-gal staining at 28 days post infarction in sham and mice with MI that received PBS, MSC-EXO or Hemin-MSC-EXO treatment. B Quantitative analysis of SA-β-gal positive area in control or mice with MI that received PBS, MSC-EXO or Hemin-MSC-EXO treatment. C Western blotting and quantitative analysis of the expression level of p16 and p21 in sham or mice with MI that received PBS, MSC-EXO or Hemin-MSC-EXO treatment. D Representative images of Troponin (red) and p21 (green) staining in sham or mice with MI that received PBS, MSC-EXO or Hemin-MSC-EXO treatment. E Quantitative analysis of Troponin⁺/p21⁺ double-positive cells in sham or mice with MI that received PBS, MSC-EXO or Hemin-MSC-EXO treatment. F Representative TEM images of mitochondria in the heart tissue from sham or mice with MI that received PBS, MSC-EXO or Hemin-MSC-EXO treatment. G Quantitative analysis of mitochondrial fragmentation in heart tissue from sham or mice with MI that received PBS, MSC-EXO or Hemin-MSC-EXO treatment. H Western blotting and quantitative analysis of the expression level of p-Drp1, Drp1, Mfn1 and Mfn2 in heart tissue from sham or mice with MI that received PBS, MSC-EXO or Hemin-MSC-EXO treatment. Data are expressed as mean ± SD. n = 6 mice for each group, **p < 0.01, ***p < 0.001, ns = not significant